SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

ARATANA THERAPEUTICS, INC. (PETX)

PETX RSS Feed
Add PETX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/20/2017 4:47:58 AM - Followers: 35 - Board type: Free - Posts Today: 0
















Welcome to Aratana Therapeutics 

Aratana Therapeutics is a biopharmaceutical company positioned to deliver innovative prescription medicines that address significant medical needs for cats and dogs (companion animals). 

The company licenses proprietary, patent-protected compounds from human pharmaceutical and biotechnology companies.  Aratana’s team of veterinary drug development experts then advance these compounds through clinical studies designed expressly for demonstrating safety and efficacy in the target specie(s).  Aratana believes the development and commercialization of these therapeutics  will permit veterinarians and companion animal owners to manage pets' medical needs safely and effectively. 

Pets are our passion because pets are family.







About Aratana Therapeutics 


Company Overview 

Companion animals are living longer and therefore are at higher risk of developing an increasing number of medical conditions such as allergies, arthritis, diabetes, cancer and obesity; however, few treatment options exist for these conditions today.   

Aratana is positioned to address this need for better pet care by bringing human science to animal health and providing veterinarians with innovative new medicines that have been designed specifically for treating pets.   

Aratana’s unique “pet-centric” approach differs fundamentally from the current standard, which often involves adjusting the dose of marketed human drugs, which are only presumed to be safe and effective in animals based on human data and veterinary experience. There is significant demand amongst veterinarians and pet owners for higher quality medicines that have been specifically studied and approved by regulatory authorities for each species. Aratana’s team of drug development and commercial experts are dedicated to developing innovative treatments in accordance with regulatory standards to meet these needs. 

Mission and Strategy 

Aratana's mission is to find, develop and commercialize safe and effective therapeutics to enhance the quality of life and strengthen the bond between people and their pets. Our strategy is to become the leading provider of therapeutics developed and approved specifically for the treatment of unmet medical needs in pets. We intend to help shape and define the pet therapeutics market by identifying, acquiring and developing high-value commercial products for companion animals in a cost effective and efficient manner. 

Programs 

Aratana is currently developing several compounds for the large and growing pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence, and a recently licensed non-opioid local anesthetic for treating post-operative pain. These compounds, which are being developed individually for both cats and dogs, are supported by substantial safety and efficacy data and, if approved by regulatory authorities, could become best- or first-in-class products in the animal health industry. 


The company is actively identifying additional programs to in-license from human health companies in order to expand its development pipeline of animal medicines





Corporate Headquarters
1901 Olathe Blvd 
Kansas City, Kansas 66103
(913) 951-2132

Other Locations
200 Clarendon Street; 54th Floor 
Boston, Massachusetts 02116
(617) 425-9226

 

Business Development Contacts
Julia A. Stephanus 
Chief Commercial Officer
(913) 951-2139
juliaastephanus@aratana.com

Erick J. Lucera, CPA, CFA 
Vice President, Corporate Development
(913) 951-2136
erickjlucera@aratana.com

 

Investor and Media Contacts
Tiberend Strategic Advisors, Inc. 
35 West 35th Street; 11th Floor
New York, New York 10001
(212) 827-0020

Investors - Joshua Drumm, PhD 
(212) 375-2665
jdrumm@tiberend.com

Media - Andrew Mielach 
(212) 375-2694
amielach@tiberend.com

 

Transfer Agent and Registrar
American Stock Transfer & Trust Company, LLC. 
(800) 937-5449










SureTrader
Interactive Brokers Advertisement
PETX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PETX News: Statement of Changes in Beneficial Ownership (4) 11/13/2017 06:06:43 PM
PETX News: Current Report Filing (8-k) 11/13/2017 08:36:40 AM
PETX News: Elanco, Aratana Announce Positive Opinion on GALLIPRANTĀ® (grapiprant tablets) in Europe 11/10/2017 11:31:00 AM
PETX News: Quarterly Report (10-q) 11/03/2017 08:04:07 AM
PETX News: Current Report Filing (8-k) 11/02/2017 04:20:20 PM
PostSubject
#306   I think we'll get some news today ... runcaly 11/20/17 04:47:58 AM
#305   Galliprant works just like other NSAIDS it just terry hallinan 11/11/17 02:45:46 PM
#304   "Terry, I think you are missing his point, terry hallinan 11/10/17 08:18:34 PM
#303   Thanks for your thoughts as well. I agree SamSalters 11/10/17 05:39:28 PM
#302   Thanks Sam. I understand. Most of my Galliprant BlueRayn 11/10/17 05:32:44 PM
#301   BlueRyan, I know I guess I didn't word SamSalters 11/10/17 05:26:49 PM
#300   Galliprant has nothing to do with appetite. Entyce BlueRayn 11/10/17 05:15:17 PM
#299   Terry, I think you are missing his point, biotech_researcher 11/10/17 04:41:32 PM
#298   I think Aratana is definitely making the right terry hallinan 11/10/17 02:57:48 PM
#297   Sam, I agree 100% on what you stated. biotech_researcher 11/10/17 02:28:18 PM
#296   Terry, I think Aratana is definitely making the SamSalters 11/10/17 01:16:40 PM
#295   A Dog of a Stock Suddenly Jumps Up terry hallinan 11/05/17 11:32:54 AM
#294   Looks like something is cooking at PETX $10.00 sandman44 09/06/17 10:31:13 AM
#293   Dogs once on kill lists now Harvey heroes terry hallinan 08/31/17 11:13:44 PM
#292   Looks like bottom is in , hoping it sandman44 08/28/17 08:40:49 PM
#291   Lol sandman, you in PETX as well? I Traderbx 08/28/17 01:19:58 PM
#290   Heading back up , reversal in effect, double sandman44 08/28/17 11:10:25 AM
#289   I like what I see ;) grabbed a sandman44 08/24/17 10:33:53 AM
#288   https://seekingalpha.com/article/4080942-aratana-might-want-grab-shares-rapidly- biotech_researcher 06/12/17 08:39:02 PM
#287   PETX- Stifel 2017 Slide Deck https://seekingalpha.com/article/4078122-aratana-t biotech_researcher 06/02/17 06:06:50 AM
#286   William Blair ups EPS to $.35 for PETX biotech_researcher 05/13/17 03:46:30 PM
#285   Thanks for the post, loading up more PETX Traderbx 05/12/17 11:28:32 AM
#284   PETX Broadfin Capital acquires a 10.6% position in biotech_researcher 05/12/17 08:09:19 AM
#283   LOL he got ya! glta tste9 04/26/17 11:53:44 AM
#282   What is your point? A month in biotechs biotech_researcher 04/26/17 11:05:07 AM
#281   Weren't you calling it junk a month ago? Traderbx 04/26/17 09:17:06 AM
#280   Company announces that it expects to have ENTYCE biotech_researcher 04/26/17 07:00:58 AM
#279   50% loss stock was 10 now its 5, diddobuyer 04/05/17 04:04:21 PM
#278   Thank you. tste9 03/28/17 09:21:59 PM
#277   Yes, we love our pets so I think biotech_researcher 03/28/17 09:14:18 PM
#276   biotech_researcher' Thanks for response as usual. tste9 03/28/17 07:40:04 PM
#275   tste, how do you know that?? Acts biotech_researcher 03/27/17 09:50:58 PM
#274   LOL, BR But, really, why so harsh. This tste9 03/27/17 07:40:28 PM
#273   Now, officially, a bow-wow stock.... :^) biotech_researcher 03/25/17 10:25:33 AM
#272   Chart is very ugly here, barely staying above diddobuyer 03/22/17 12:22:33 PM
#271   Why retract his statement!? What timeline are Rhew123 03/19/17 08:58:13 PM
#270   Mr. Popeye, your quote: biotech_researcher 03/18/17 01:16:48 PM
#269   Super helpful insight Rhew123 03/17/17 11:18:40 AM
#268   Garbage stock diddobuyer 03/17/17 10:46:42 AM
#267   Can you throw him really far? Or is Rhew123 03/16/17 10:53:19 AM
#266   I value Bret Jensen as far as I biotech_researcher 03/16/17 10:46:53 AM
#265   http://seekingalpha.com/article/4055451-2-small-biotechs-10-buy-now?ifp=0 tste9 03/16/17 10:15:39 AM
#264   LOL ! you crack me up. You are tste9 03/16/17 09:34:32 AM
#263   SGYP has too many shares outstanding to make biotech_researcher 03/16/17 09:19:58 AM
#262   Nice, I'll take a peek - my other Rhew123 03/16/17 09:04:23 AM
#261   Glad you got out in time, me too. tste9 03/16/17 08:57:52 AM
#260   I'm not sure yet, to be honest - Rhew123 03/16/17 08:53:08 AM
#259   Rhew123; You think it's OK to get back tste9 03/16/17 08:32:36 AM
#258   I believe that they said a good chunk Rhew123 03/15/17 10:29:55 AM
#257   So, what was the Q4 $10.7 million inventory biotech_researcher 03/15/17 03:50:20 AM
PostSubject